May 9 |
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress
|
May 8 |
We Think Arvinas (NASDAQ:ARVN) Can Afford To Drive Business Growth
|
May 7 |
Arvinas, Inc. (ARVN) Reports Q1 Loss, Lags Revenue Estimates
|
May 7 |
Arvinas GAAP EPS of -$0.97 beats by $0.37, revenue of $25.3M misses by $6.76M
|
May 7 |
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
|
May 2 |
Why Earnings Season Could Be Great for Arvinas (ARVN)
|
May 2 |
Arvinas to Present at Upcoming Investor Conferences
|
May 1 |
Arvinas (ARVN) Upgraded to Buy: What Does It Mean for the Stock?
|
Apr 30 |
Earnings Preview: Rhythm Pharmaceuticals, Inc. (RYTM) Q1 Earnings Expected to Decline
|
Apr 26 |
Arvinas, Inc. (ARVN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
|